Sonoma Pharmaceuticals, Inc. (SNOA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 1.6400 |
| Open | 1.6200 |
| Bid | 1.6700 x 1000 |
| Ask | 1.6700 x 1100 |
| Day's Range | 1.5889 - 1.7000 |
| 52 Week Range | 1.0000 - 4.2500 |
| Volume | |
| Avg. Volume | 1,890,524 |
| Market Cap | 5.094M |
| Beta (5Y Monthly) | 1.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.4160 |
| Earnings Date | Feb 09, 2023 - Feb 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SNOA
Related Research
- Sonoma Pharmaceuticals, Inc.Analyst Report: Bristol-Myers Squibb CompanyBristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.RatingFair ValueEconomic Moat2 days agoMorningstar
- ACCESSWIRE
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that it has entered into a distribution agreement with Daewoong Pharmaceutical Co., Ltd. for the marketing and distribution of PrimocynTM Skin Solution products
- ACCESSWIRE
Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care, today announced that Microcyn® Rx products have received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).
- ACCESSWIRE
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas
Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including dermatology, eye, oral and nasal care, and wound care today announced that it has launched a line of office dispense products exclusively for skin care professionals.
